← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Texas Tech University Health Sciences Center At El Paso
El Paso, TX
$12,316,867
Total funding
20
Grants
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,607,851 · 17
DOD$1,452,124 · 2
NSF$256,892 · 1
By mechanism
R01$3,996,156 · 5
U01$2,796,768 · 2
R15$1,866,670 · 4
—$1,709,016 · 3
R00$1,118,116 · 2
R16$320,001 · 1
Investigators at Texas Tech University Health Sciences Center At El Paso
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
UNDERSTANDING PHYSIOLOGICAL PREVENTION OF BREAST CANCER: EFFECT OF EARLY FIRST FULL-TERM PREGNANCY$1,146,128
· FY2017 · Department of the Army
Characterizing the Effects of Chronic Substance Misuse on Auditory and Vestibular Function$589,430
R01 · FY2023 · DC
A novel Quadruple Knockout Mtb vaccine against tuberculosis$492,258
R15 · FY2021 · AI
New Nasal Spray Influenza Vaccine for Children$480,000
R15 · FY2023 · HD
G0S2 and lipid metabolism in the regulation of hematopoietic development$480,000
R15 · FY2024 · HL
A novel hyper-immunogenic low virulent BCG vaccine against tuberculosis$462,379
R01 · FY2023 · AI
A novel hyper-immunogenic low virulent BCG vaccine against tuberculosis$458,789
R01 · FY2025 · AI
A novel hyper-immunogenic low virulent BCG vaccine against tuberculosis$452,019
R01 · FY2024 · AI
The functions of the zinc finger protein ZPR1 in R-loop metabolism and neurodegeneration.$444,825
R01 · FY2021 · NS
Characterizing the Effects of Chronic Substance Misuse on Auditory and Vestibular Function$432,160
R01 · FY2024 · DC
The functions of the zinc finger protein ZPR1 in R-loop metabolism and neurodegeneration.$424,271
R01 · FY2022 · NS
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2022 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2023 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$386,809
U01 · FY2019 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$384,000
U01 · FY2024 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$382,355
U01 · FY2020 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$350,557
U01 · FY2025 · DK
Novel role of mitochondrial carrier protein PSAP in regulation of both apoptosis and autophagy in ALS$335,237
R01 · FY2025 · NS
NEW LIVE ATTENUATED ZIKA VIRUS VACCINE$305,996
· FY2018 · Defense Health Agency
ISS/Collaborative Research: Studying the Effects of Microgravity on 3D Cardiac Organoid Cultures$256,892
· FY2019 · ENG